Differential effect of the expression of TGF‐β pathway inhibitors, Smad‐7 and Ski, on invasive breast carcinomas: relation to biologic behavior
Source: Apmis, Volume 120, Number 2, 1 February 2012 , pp. 92-100(9)
Abstract:Theohari I, Giannopoulou I, Magkou C, Nomikos A, Melissaris S, Nakopoulou L. Differential effect of the expression of TGF‐β pathway inhibitors, Smad‐7 and Ski, on invasive breast carcinomas: relation to biologic behavior. APMIS 2011.
The aim of our study was to investigate the expression of Smad‐7 and Ski proteins in invasive breast carcinomas, to determine their clinicopathological value and their influence on carcinomas biologic behavior. Immunohistochemistry was applied on 150 invasive breast carcinomas to detect the expression of Smad‐7 and Ski. Their correlation to clinicopathologic parameters and markers of metastasis was statistically processed using chi‐squared test. Overall and disease‐free survival was assessed using Kaplan–Meier test and log‐rank statistics. Smad‐7 was immunodetected in the cytoplasm of cancer cells in 60%, whereas Ski was immunodetected in the cytoplasm and nuclei in 44.5% and 17.6% of the cases, respectively. Smad‐7 expression was positively correlated with tumor size, stage, matrix metalloproteinase (MMP)‐9, and MMP‐14. Cytoplasmic Ski expression was negatively associated with tumor size, stage, and lymph node status, and its nuclear expression was negatively related to histologic grade. Cytoplasmic Ski expression was associated with longer overall and disease‐free survival. It appears that two negative regulators of the transforming growth factor‐β pathway, Smad‐7 and Ski, behave differentially in invasive breast carcinomas. Smad‐7 appears to be related with an aggressive phenotype, whereas Ski expression is related to a less aggressive behavior and positively influences patients’ survival.
Document Type: Research Article
Affiliations: 1: First Department of Pathology, Medical School, University of Athens, Athens 2: Department of Pathology, “Evaggelismos” General Hospital, Athens 3: Department of Pathology, “Aslipieio” General Hospital, Voula, Greece
Publication date: 2012-02-01